Steadtrust LLC Grows Stock Position in InMode Ltd. $INMD

Steadtrust LLC raised its holdings in InMode Ltd. (NASDAQ:INMDFree Report) by 251.9% in the second quarter, HoldingsChannel reports. The institutional investor owned 91,500 shares of the healthcare company’s stock after acquiring an additional 65,500 shares during the quarter. Steadtrust LLC’s holdings in InMode were worth $1,338,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Steel Partners Holdings L.P. raised its position in shares of InMode by 154.8% in the 1st quarter. Steel Partners Holdings L.P. now owns 1,795,361 shares of the healthcare company’s stock valued at $24,561,000 after purchasing an additional 1,090,697 shares during the last quarter. Renaissance Technologies LLC grew its position in InMode by 6.1% during the 1st quarter. Renaissance Technologies LLC now owns 2,586,218 shares of the healthcare company’s stock worth $35,379,000 after purchasing an additional 149,800 shares during the last quarter. State of Wyoming purchased a new stake in InMode during the 4th quarter worth approximately $624,000. DGS Capital Management LLC increased its stake in InMode by 127.7% during the 4th quarter. DGS Capital Management LLC now owns 79,613 shares of the healthcare company’s stock valued at $1,170,000 after purchasing an additional 44,654 shares in the last quarter. Finally, Systematic Financial Management LP increased its stake in InMode by 6.7% during the 1st quarter. Systematic Financial Management LP now owns 1,154,457 shares of the healthcare company’s stock valued at $15,793,000 after purchasing an additional 72,041 shares in the last quarter. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Price Performance

NASDAQ INMD opened at $15.31 on Monday. InMode Ltd. has a 1 year low of $12.72 and a 1 year high of $16.74. The company has a market capitalization of $880.02 million, a PE ratio of 12.45 and a beta of 1.89. The company has a fifty day moving average of $14.52 and a 200 day moving average of $14.26.

InMode (NASDAQ:INMDGet Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The healthcare company reported $0.35 earnings per share for the quarter, hitting the consensus estimate of $0.35. The company had revenue of $95.59 million for the quarter, compared to the consensus estimate of $94.89 million. InMode had a return on equity of 11.99% and a net margin of 20.69%.The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the firm earned $0.47 EPS.

Analyst Upgrades and Downgrades

INMD has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of InMode in a report on Thursday. Barclays set a $19.00 target price on InMode and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Robert W. Baird reduced their target price on InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, InMode currently has an average rating of “Hold” and an average price target of $16.00.

Get Our Latest Report on InMode

About InMode

(Free Report)

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

Featured Stories

Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMDFree Report).

Institutional Ownership by Quarter for InMode (NASDAQ:INMD)

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.